Yongchang Zhang
Hunan Cancer Hospital · Hunan Province Tumor Hospital · zhangyongchang@csu.edu.cn
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
39
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in non-small cell lung cancer
220
PubMed author-name match
Trials
Studies that name Yongchang Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07878871 · Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyHunan Province Tumor Hospital · not yet recruiting · Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer · principal investigator
- Ph1NCT07179081 · A Study of AL58805 in Patients With Advanced TumorsAdvenchen Laboratories Nanjing Ltd. · recruiting · Advanced Tumors · principal investigator
- Ph2NCT06962865 · A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRemeGen Co., Ltd. · recruiting · Non-Small Cell Lung Cancer · study director
- Ph1/Ph2NCT06521034 · First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung CancerYongchang Zhang · completed · Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Sensitizing Mutation · principal investigator
- Ph2NCT06440954 · Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesHunan Province Tumor Hospital · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT06355609 · Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RWHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT06348927 · Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLCHunan Province Tumor Hospital · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06220318 · Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsFujian Haixi Pharmaceuticals Co., Ltd. · active not recruiting · Solid Tumor · principal investigator
- N/ANCT06174857 · Efficacy of Osimertinib in Patients With Lung CancerHunan Province Tumor Hospital · unknown · Advanced Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06081907 · The Efficacy and Safety of IBI363 in Solid TumorsHunan Province Tumor Hospital · recruiting · Advanced Solid Tumor · principal investigator
- N/ANCT05984017 · A Non-interventional Study With Advanced Lung Squamous Cell CarcinomaHunan Province Tumor Hospital · unknown · Advanced Lung Squamous Cell Carcinoma · principal investigator
- Ph3NCT05549037 · Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- N/ANCT05450081 · Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in PatientsHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05284539 · Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer · principal investigator
- N/ANCT05261438 · Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCHunan Province Tumor Hospital · completed · Non-squamous NSCLC · principal investigator
- N/ANCT05129462 · Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC PatientsHunan Province Tumor Hospital · completed · Non Small Cell Lung Cancer · principal investigator
- N/ANCT05059951 · Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph3NCT05055908 · Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsHunan Province Tumor Hospital · recruiting · Lung Cancer · principal investigator
- N/ANCT05055999 · Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung CancerHunan Province Tumor Hospital · completed · Extensive Stage Small Cell Lung Cancer · principal investigator
- N/ANCT05055947 · Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung CancerHunan Province Tumor Hospital · completed · Extensive Stage Small Cell Lung Cancer · principal investigator
- N/ANCT05023837 · Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeHunan Province Tumor Hospital · completed · Uncommon Pathological Types of Lung Cancer · principal investigator
- Ph2NCT05014464 · ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04997382 · Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04951947 · JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung CancerHunan Province Tumor Hospital · unknown · Small-cell Lung Cancer · principal investigator
- Ph2NCT04937972 · SHR-1701 Combined With Fluzoparib in Lung Squamous Cell CarcinomaHunan Province Tumor Hospital · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT04777084 · The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.Hunan Province Tumor Hospital · recruiting · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT04324164 · Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- N/ANCT04324151 · Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLCHunan Province Tumor Hospital · unknown · Non Small Cell Lung Cancer · principal investigator
- N/ANCT04324125 · Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCHunan Province Tumor Hospital · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04322578 · Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- N/ANCT04322591 · Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04322890 · Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation · principal investigator
- Ph2/Ph3NCT04322617 · Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04144569 · PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLCYongchang Zhang · unknown · HER2 Insertion Mutation Positive Advanced NSCLC · principal investigator
- Ph2NCT03798743 · Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS StudyHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- N/ANCT03647098 · Survival Outcomes of Lung CancerHunan Province Tumor Hospital · recruiting · Lung Cancer · principal investigator
- N/ANCT03647111 · Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung CancerHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- N/ANCT03646994 · Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung CancerHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03646968 · Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save StudyYongchang Zhang · unknown · Non-Squamous Non Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:02 UTC. The ranking covers the 200 most relevant of 220 PubMed records, and a shared surname and initials can bring in a namesake. All 220 on PubMed
- 3,498 citationsRCR 88.2
- 1,234 citationsRCR 24.3
- 605 citationsRCR 17.5
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.J Thorac Oncol · 2020520 citationsRCR 19.8
- Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.Nat Med · 2020447 citationsRCR 17.1
- 408 citationsRCR 19.3
- 392 citationsRCR 42.0
- 391 citationsRCR 10.4
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.Lancet Oncol · 2013386 citationsRCR 10.6
- 342 citationsRCR 12.0